Table 4.
DMT use in Trim+2 as compared to that in Trim-2 among pregnancies ended between 2010 and 2021 in women who were on DMT during trimester-2.
| DMTs used during trimester+2 a | Total | |||
|---|---|---|---|---|
| Same DMT | Different DMT | No DMT | ||
| DMTs used during trimester-2 b | ||||
| Beta-interferon | 1796 (56.5) | 632 (19.9) | 749 (23.6) | 3177 (100.0) |
| Glatiramer acetate | 983 (53.0) | 444 (24.0) | 426 (23.0) | 1853 (100.0) |
| Teriflunomide | 155 (53.3) | 53 (18.2) | 83 (28.5) | 291 (100.0) |
| Dimethyl fumarate | 587 (62.4) | 143 (15.2) | 210 (22.3) | 940 (100.0) |
| Fingolimod | 463 (70.6) | 104 (15.9) | 89 (13.6) | 656 (100.0) |
| Natalizumab | 1031 (73.9) | 204 (14.6) | 161 (11.5) | 1396 (100.0) |
| Anti-CD20 c | 159 (73.6) | 7 (3.2) | 50 (23.1) | 216 (100.0) |
| Azathioprine | 62 (59.6) | 11 (10.6) | 31 (29.8) | 104 (100.0) |
| Other DMTs d | 15 (48.3) | 2 (6.2) | 14 (45.2) | 31 (100.0) |
| Total | 5251 (60.6) | 1600 (18.5) | 1813 (20.9) | 8664 (100.0) |
DMT: disease-modifying therapy.
a
During trimester+1 and trimester+2 for anti-CD20.
b
Semester-2 for anti-CD20.
c
Ocrelizumab and rituximab.
d
Mycophenolate mofetil, methotrexate, and biotin.